Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
cholecalciferol 1 nephrologydiseasesdrugs
chronic kidney disease 7 nephrologydiseases
paricalcitol 17 nephrologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cholecalciferol 5366 molecule) and vitamin D3 (cholesterol-derived molecule) [[20]]. 7-Dehydrocholesterol (pro-vitamin D3) and cholecalciferol (pre-vitamin D3) are precursors of vitamin D3, while ergocalciferol (pre-vitamin D2) is the precursor
paricalcitol 7333 mineralisation and turnover. Calcitriol or vitamin D receptor activator (VDRA) treatment including paricalcitol , doxercalciferol and alfacalcidol is associated with the suppression of PTH levels, but, at the same
paricalcitol 13043 (1,25-dihydroxyvitamin D2).Animal studies, demonstrated that calcitriol and related analogues including paricalcitol enhanced diastolic relaxation and decreased end-diastolic pressures, lowered cardiac mRNA expression
paricalcitol 13920 placebo-controlled trial [[39]] examining the hypothesis that treatment with oral activated vitamin D ( paricalcitol ), decreases LV mass in stages 3–5 CKD patients with LV hypertrophy and that it improves systolic and
paricalcitol 14111 it improves systolic and diastolic dysfunction in CKD, demonstrated that 52 weeks of treatment with paricalcitol (at a dose that is sufficient to suppress secondary hyperparathyroidism), failed to reduce LV mass and
paricalcitol 14370 hypertrophy and it did not modify LV systolic function nor diastolic function. Also, in this study paricalcitol treatment was associated with hypercalcaemia, which occurred in 43.3% of participants. A meta-analysis
paricalcitol 15597 retrospective cohorts) [[7]] demonstrated that the therapy with various analogues of active vitamin D ( paricalcitol , calcitriol) was associated with differences in patients’ survival. It turned out that treatment with
paricalcitol 15714 calcitriol) was associated with differences in patients’ survival. It turned out that treatment with paricalcitol lowered mortality to a slightly greater extent than calcitriol therapy, which could be explained by
paricalcitol 16426 (HR, 0.43 95% CI, 0.29–0.63; p < 0.001), respectively. It has been observed that patients receiving paricalcitol had a survival advantage over those who received calcitriol (HR, 0.95; 95% CI, 0.91–0.99; p < 0.001).
paricalcitol 16569 those who received calcitriol (HR, 0.95; 95% CI, 0.91–0.99; p < 0.001). Alfacalcidol, calcitriol, paricalcitol and not otherwise specified active vitamin D treated patients had a 46% (HR, 0.54; 95% CI, 0.37–0.80),
paricalcitol 16893 0.57–0.72) lower overall mortality risk in comparison to untreated patients. Moreover, with calcitriol, paricalcitol and not otherwise specified active vitamin D supplementation resulted in 26% decrease (HR, 0.74; 95%
paricalcitol 17351 patients and CKD patients not on dialysis. According to other studies, vitamin D (or its analogues – paricalcitol , calcitriol) administration to haemodialysis patients is associated with significant reduction in the
paricalcitol 17568 risk of all-cause death and of cardiovascular death. The difference in survival of patients receiving paricalcitol was significant at 12 months and increased with time (p < 0.001) [[60]]. The effect of vitamin D analogues
paricalcitol 17786 analogues therapy may also depend on mean daily or weekly doses. In haemodialysis patients, weekly doses of paricalcitol above 15.0 μg were shown to result in an 18% reduction of mortality risk [[61]]. Too low doses of vitamin
paricalcitol 20234 hypertrophy, and preserved left ventricular ejection fraction, analysed whether 48-week treatment with paricalcitol (19-nor-1,25-(OH)2 vitamin D2) reduced left ventricular mass, enhanced diastolic function, diminished
paricalcitol 20458 events, and improved the level of cardiac biomarkers in patients with LVH and CKD [[14]]. In this study, paricalcitol at dose 2 μg/d did not reduce left ventricle mass index (LVMI) and did not alter certain echocardiographic
paricalcitol 20785 blood levels of BNP, especially in those with evident LVH at baseline. Despite being well-tolerated, paricalcitol treatment was in some patients (20.9%) associated with hypercalcemia. Moreover, paricalcitol also increased
paricalcitol 20878 well-tolerated, paricalcitol treatment was in some patients (20.9%) associated with hypercalcemia. Moreover, paricalcitol also increased serum creatinine and consequently reduced creatinine-based measures of estimated glomerular
Select Disease Character Offset Disease Term Instance
chronic kidney disease 881 robert.olszewski@me.comPublication date (epub): 6/2018Publication date (collection): 6/2018AbstractIn patients suffering from chronic kidney disease (CKD), the prevalence of cardiovascular disease is much more common than in the general population.
chronic kidney disease 1237 survival benefit in haemodialysis patients. Vitamin D deficiency is present even in the early stages of chronic kidney disease . The results of experimental studies have revealed the relationship between vitamin D deficiency and
chronic kidney disease 2230 outcomes and whether it is safe to be used in CKD patients.1. IntroductionIn patients suffering from chronic kidney disease (CKD), the prevalence of cardiovascular disease is much more common than in the general population [[1]].
chronic kidney disease 3007 diabetes, and dyslipidaemia [[6],[7],[8],[9]]. Vitamin D deficiency is present even in the early stages of chronic kidney disease . Numerous observational studies have confirmed low levels of both total 25-hydroxyvitamin D 25(OH)D
chronic kidney disease 3582 survival benefit in haemodialysis patients.Cascade of changes in mineral metabolism occur in the course of chronic kidney disease resulting in the increase in the level of circulating parathyroid hormone and in abnormalities associated
chronic kidney disease 3964 [[5],[12]]. Management of elevated PTH levels in CKD has posed a challenge for several decades.Patients with chronic kidney disease are frequently suffering from the deficiency of 1,25-dihydroxyvitamin D3 (calcitriol) due to the lack
chronic kidney disease 20073 Renal Failure—Induced Cardiac Morbidity) conducted in 11 countries and involving 227 patients with chronic kidney disease , mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, analysed

You must be authorized to submit a review.